EuroSC - The European Schizophrenia Cohort

Head :Jean Michel Azorin
Bebbington Paul

Last update : 09/05/2017 | Version : 1 | ID : 73208

General

Identification

Detailed name	The European Schizophrenia Cohort
Sign or acronym	EuroSC
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL

General Aspects

Medical area	Psychology and psychiatry
Pathology (details)	Schizophrenia
Health determinants	Healthcare system and access to health care services Medicine
Keywords	schizophrenia, management, treatment, quality of life, care, cost

Scientific investigator(s) (Contact)

Name of the director	Jean Michel
Surname	Azorin
Phone	+33 (0)4 91 74 48 15
Email	Jean-michelRoch.AZORIN@ap-hm.fr jazorin@ap-hm.fr
Organization	AP-HM Southern Regional Hospitals
Name of the director	Bebbington
Surname	Paul

Address	Wolfson Building 48 Riding House Street London W1W 7EY, UK
Email	p.bebbington@ucl.ac.uk
Organization	Royal Free and University College Medical School, UCL

Collaborations

Participation in projects, networks and consortia	Yes
Details	EuroSC Research Group (Germany, England, France)

Funding

Funding status	Mixed
Details	Lundbeck A/S ; German Federal Ministry of Education and Research

Governance of the database

Sponsor(s) or organisation(s) responsible	Royal Free and University College Medical School.. Pour la partie Francaise : Hôpital Sainte Marguerite , Marseille
Organisation status	Public

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No

Database objective

Main objective	The main aim of EuroSC is to report on the different

	types of treatment and care, as well as clinical outcome. Secondary aims include: assessment of treatment requirements in relation to outcome, calculation of resource usage with regards to different care methods and identification of prognostic factors.
Inclusion criteria	Patients between 18 and 64 years old at baseline; Established schizophrenia diagnosis; Participant consent

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male Woman
Geography area	International
Detail of the geography area	Europe ? France (Lille, Lyon, Marseilles, Clermont-Ferrand, Toulon)

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	1998
Date of last collection (YYYY or MM/YYYY)	2002

Size of the database

Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	France: 288; UK: 302; Germany: 618

Data

Database activity	Data collection completed
Type of data collected	Clinical data Declarative data

Clinical data (detail)	Direct physical measures
Details of collected clinical data	Psychiatric history, sociodemographic information, diagnosis, treatment, psychiatric and social state (SCAN SCAN, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), Global Assessment of Relational Functioning (GARF)) medication use and side effects, treatment adherence (Rating of Medication Influences (ROMI) Scale,), healthcare system pathway and usage of service resources.
Declarative data (detail)	Face to face interview
Details of collected declarative data	Quality of Life (Medical Outcome Study Short Form 36 (SF36), Social and Occupational Functioning Assessment Scale (SOFAS), Quality of Life Interview (QoLI), EuroQoL)
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health care consumption and services Quality of life/health perception
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption

Procedures

Data collection method	By medical staff in the centres concerned.
Participant monitoring	Yes
Details on monitoring of participants	Every 6 months for 2 years following enrolment.
Links to administrative sources	No

Promotion and access

Promotion

Link to the document	http://www.biomedcentral.com/1472-6963/12/269#B4
Link to the document	http://tinyurl.com/PUBMED-EUROSC

Access

Terms of data access (charter for data provision, format of data, availability delay)	Contact the scientist in charge.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only